Vancomycin (V) | Non-Vancomycin (NV) | P value | |
---|---|---|---|
No. of Patients | 110 | 86 | |
Mean Age at Op. (years) | 73.7 ± 9.8 (49–82) | 72.5 ± 10.6 (55–81) | 0.413 |
Body Mass Index (BMI) | 21.8 ± 3.5 (15.9–32.9) | 22.2 ± 3.8 (16.7–34.6) | 0.445 |
Gender | 0.689 | ||
Male | 48 | 40 | |
Female | 62 | 46 | |
Pathologic Lesions | 0.927 | ||
2 levels | 36 | 27 | |
3 levels | 58 | 47 | |
4 levels | 16 | 12 | |
Co-morbidities | 0.577 | ||
Diabetes mellitus | 23 | 14 | |
BMI > 30 | 2 | 3 | |
Rheumatoid arthritis | 0 | 1 | |
Steroid Used | 5 | 4 | |
Smoker | 26 | 14 | |
Functional Outcomes | |||
Visual analogue scale over back | 4.2 ± 2.1(2–8) | 4.3 ± 2.4 (1–8) | 0.746 |
Visual analogue scale over leg | 5.0 ± 1.6 (4–7) | 4.9 ± 1.8 (4–8) | 0.682 |
Oswestry Disability Index (ODI) | 54.8 ± 12.6 (38–70) | 55.7 ± 13.3(24–74) | 0.629 |
Mean follow-up times (months) | 38.3 ± 6.2 (36–48) | 53.1 ± 5.7(48–60) | 0.000 |